Three Dividend Catalysts Before the Calendar Flips

A healthcare giant's check clears Monday. A specialty insurer just dropped a 50-cent special. And a New England utility quietly extended a 28-year streak. Plus three names on the watch list and ex-dates worth circling.

Big Shift (Sponsored)

Elon Musk: Buy Alert

The world's richest man just launched a new $480 trillion disruption, which could make you massive gains this summer.

It has nothing to do with space, robots or AI.

It's much, much bigger.

Full details here.

Pharma

J&J Is Skipping Obesity Drugs to Double Down on Cancer and Brain Health

Johnson & Johnson (NYSE: JNJ) is staying out of the obesity drug race and focusing its next growth push on cancer, neuroscience, medical devices, and AI-enabled healthcare.

The decision separates J&J from drugmakers chasing the GLP-1 weight-loss boom and gives the company a cleaner path around areas where it already wants deeper leadership.

Cancer Gets the Priority

J&J is aiming to become a larger force in oncology, with existing strength in multiple myeloma and lung cancer, plus recent dealmaking in prostate cancer.

That creates a more focused pipeline story than chasing an obesity market already crowded with powerful leaders.

Follow the capital, and you find J&J choosing depth over crowd noise.

The company is placing more weight on disease areas with serious unmet need that can support long product cycles, stronger pricing power, and durable medical demand.

Neuroscience Stays in the Plan

Dementia and neurodegenerative diseases remain difficult areas, but they also carry enormous healthcare demand.

J&J keeping research dollars in brain health signals a willingness to stay in categories where breakthroughs can change the company’s long-term profile.

Skip the obesity hype, and you land on the bigger company decision.

J&J is trying to build a more focused healthcare machine around cancer, neuroscience, and advanced medical technology, rather than joining a market where rivals already control the front line.

JNJ currently trades at $233 and pays a dividend of $5.36 per share, a yield of 2.29%.

Energy

Chevron Expanded Its Mediterranean Exploration Footprint

Chevron (NYSE: CVX) is expanding its offshore position in Greece by taking a 70% operating stake in Block 10 from Helleniq Energy, a Greek energy company that will retain the remaining interest.

The deal gives Chevron another Mediterranean exploration block and expands its partnership in Greece to five offshore concessions.

The move strengthens Chevron’s search for future oil and gas resources in a region gaining more attention as Europe looks for secure energy options closer to home.

Block 10 already has seismic work completed, giving Chevron a more developed starting point for evaluating future drilling targets.

Mediterranean Acreage Gets Bigger

Chevron is not entering Greece with a single isolated project.

The company now has a broader offshore position across the Southern Ionian, Crete, and Peloponnese areas, creating a wider platform for exploration planning.

Map the five blocks together, and you find the Chevron building on a regional scale, not testing one small prospect.

More acreage gives the company better room to compare geology, manage risk, and decide where future drilling capital should go.

Greece Becomes a Larger Energy Option

Europe’s energy needs have changed, and companies with offshore experience are looking again at regions that can add future supply.

Chevron’s deeper Greece position gives it exposure to potential resources while sharing early-stage risk with a local partner.

If the next technical steps support drilling, you can clearly trace the business upside: Chevron adds another frontier to its global exploration map while building a stronger Mediterranean growth option.

CVX currently trades at $179 and pays a dividend of $7.12 per share, a yield of 3.98%.

Tax Strategy (Sponsored)

3 Overlooked Ways to Potentially Reduce Capital Gains Tax

Capital gains taxes can take a bigger bite out of your profits than expected.

Fortunately, some deductions may help reduce the impact — including:

• Investment-related expenses

• Cost basis adjustments

• Certain real estate selling costs

Because rules and eligibility vary, many investors turn to fiduciary financial advisors for guidance.

Find an Advisor Match.

Enterprise

Equinix Is Building the Testing Ground for Corporate AI Systems

Equinix (NASDAQ: EQIX) is expanding its collaboration with Cisco and Nvidia to bring AI factory infrastructure across its global data center network.

The rollout gives enterprise customers a more standardized way to deploy AI systems inside Equinix facilities, with the power, cooling, networking, and security needed for heavier AI workloads.

Testing Becomes Part of the Product

Equinix is also working with Presidio, an IT services and digital infrastructure company, to create a testing lab inside its data centers.

The lab gives customers a place to test and refine AI infrastructure before rolling it out across a wider business.

That puts your attention on execution, not hype. Equinix is providing companies with a controlled environment to prove that AI systems work before they commit to larger deployments.

Partnerships Expand the Platform

Cisco brings networking and security, Nvidia brings AI infrastructure standards, and Equinix brings the global data center footprint. Together, the setup gives customers a clearer path from planning to deployment.

For Equinix, the move strengthens its role as a global meeting point for AI infrastructure.

As companies race to turn AI plans into working systems, Equinix is putting its data centers at the point where AI stops being a boardroom promise and starts running the tools you actually use.

EQIX currently trades at $1098 and pays a dividend of $20.64 per share, a yield of 1.88%.

Nasdaq Inc (NDAQ) raised its dividend to $0.31, a 14.81% jump from $0.27. New trailing yield around 1.48%.

Chesapeake Utilities (CPK) lifted its payout 7.30% to $0.735, extending a 22-year growth streak. Yield's now near 2.10%.

CNO Financial Group (CNO) bumped its dividend 5.88% to $0.18, marking 13 consecutive years of growth.

Enterprise Financial Services Corp (EFSC) raised its dividend 3.03% to $0.34, its 11th straight annual hike.

TPG RE Finance Trust (TRTX) slashed its dividend 38.56% to $0.24, down from $0.3906. New trailing yield: 11.17%. That's the market pricing in more pain.

Amrize (AMRZ) cut its payout to $0.11. A 75% chop from $0.44.

Healthcare Realty Trust (HR) is still running at its reduced $0.24 quarterly payout after last year's 23% cut. Morgan Stanley flagged it as a turnaround candidate this month. Yield's now near 4.7%.

Elon Lab Scrutiny (Sponsored)

Why are companies flying spy planes over Elon’s closely-guarded AI lab?

Elon did the seemingly impossible – far faster than anyone expected…

And it's sent the tech industry into PANIC MODE.

ChatGPT, Claude, Google Gemini, and DeepSeek could soon become obsolete.

And three little-known firms could soar 10X or higher as a result.

Get the details here.

*This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

Everything Else

• 🌱 A free report names seven stocks designed to quietly compound wealth including a healthcare leader with 61 consecutive years of unbroken growth.

• 📈 June 2026 brought strong, across-the-board improvement in the outlook for S&P 500 quarterly dividends, with the current Q2 quarter seeing the biggest month-over-month gain, which is exactly the kind of "boring" headline income investors live for. 

• 🔧 W.W. Grainger increased its dividend by 10.2% in 2026 after identical 10.2% increases in both 2025 and 2024, with its five-year dividend growth rate now exceeding 8% and the stock generating a 30.9% total return this year — turns out selling industrial nuts and bolts is wildly profitable. 

• 🏭 Linde, the world's largest industrial gas company, raised its dividend by 6.7% in 2026 and has delivered dividend growth approaching 8% annually over the past decade, quietly compounding while flashier names hog the spotlight. 

• 🥜 John B. Sanfilippo & Son announced a special dividend of $1.50 per share, returning $17.6 million to shareholders, with a low payout ratio of 15.7% keeping dividends well-covered by earnings and cash flows — proof that nuts pay better than you'd think.